Ann: Final Nyrada Phase I Clinical Trial Cohort to Commence, page-3

14 July 2025 Sydney, Australia

Final Nyrada Phase I Clinical Trial Cohort to Commence

Highlights:

• Cohort 6 approved to commence, marking the final stage of Nyrada’s Phase I clinical trial
of Xolatryp™.
• Safety Review Committee for Nyrada’s Phase I clinical trial has cleared progression
following review of safety and pharmacokinetic data from Cohort 5.
• Cohort 5 received the highest concentration to date via a 3-hour intravenous infusion –
the human equivalent dose that showed 42% cardioprotection in a preclinical study.
• No safety concerns were identified in Cohort 5, with no dose-limiting toxicities or
adverse effects reported.
Nyrada Inc (ASX:NYR), a clinical-stage drug discovery and development company focused